1. Home
  2. NMRA vs POLE Comparison

NMRA vs POLE Comparison

Compare NMRA & POLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NMRA
  • POLE
  • Stock Information
  • Founded
  • NMRA 2019
  • POLE 2024
  • Country
  • NMRA United States
  • POLE United States
  • Employees
  • NMRA N/A
  • POLE N/A
  • Industry
  • NMRA
  • POLE
  • Sector
  • NMRA
  • POLE
  • Exchange
  • NMRA Nasdaq
  • POLE NYSE
  • Market Cap
  • NMRA 287.6M
  • POLE 296.0M
  • IPO Year
  • NMRA 2023
  • POLE 2024
  • Fundamental
  • Price
  • NMRA $1.28
  • POLE $10.11
  • Analyst Decision
  • NMRA Buy
  • POLE
  • Analyst Count
  • NMRA 8
  • POLE 0
  • Target Price
  • NMRA $10.14
  • POLE N/A
  • AVG Volume (30 Days)
  • NMRA 1.3M
  • POLE 3.7K
  • Earning Date
  • NMRA 03-03-2025
  • POLE 01-01-0001
  • Dividend Yield
  • NMRA N/A
  • POLE N/A
  • EPS Growth
  • NMRA N/A
  • POLE N/A
  • EPS
  • NMRA N/A
  • POLE N/A
  • Revenue
  • NMRA N/A
  • POLE N/A
  • Revenue This Year
  • NMRA N/A
  • POLE N/A
  • Revenue Next Year
  • NMRA N/A
  • POLE N/A
  • P/E Ratio
  • NMRA N/A
  • POLE N/A
  • Revenue Growth
  • NMRA N/A
  • POLE N/A
  • 52 Week Low
  • NMRA $1.26
  • POLE $9.94
  • 52 Week High
  • NMRA $17.19
  • POLE $11.16
  • Technical
  • Relative Strength Index (RSI)
  • NMRA 26.96
  • POLE N/A
  • Support Level
  • NMRA $1.26
  • POLE N/A
  • Resistance Level
  • NMRA $1.48
  • POLE N/A
  • Average True Range (ATR)
  • NMRA 0.13
  • POLE 0.00
  • MACD
  • NMRA 0.08
  • POLE 0.00
  • Stochastic Oscillator
  • NMRA 4.44
  • POLE 0.00

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.

About POLE ANDRETTI ACQUISITION CORP. II

Andretti Acquisition Corp II is a blank check company.

Share on Social Networks: